Advertisement

Topics

Companies Related to "More Positives PCSK9 inhibitors Hypothesis" [Most Relevant Company Matches] RSS

21:33 EDT 22nd October 2018 | BioPortfolio

Here are the most relevant search results for "More Positives PCSK9 inhibitors Hypothesis" found in our extensive corporate database of over 50,000 company records.

Showing "More Positives PCSK9 inhibitors Hypothesis" Companies 1–25 of 167

Relevant

Amura Holdings Ltd

Amura has two complementary technology platforms which enable rapid and innovative drug discovery. AMcore™, the bicyclic core molecular scaffold chemistry and the computational screening and design platform, ProtoDiscovery™. Amura has four NCE discovery programmes based on AMcore™:An Osteoporosis programme based on cathepsin K inhibitors, A Psoriasis programme based on a cathepsin S inhibit...


BioImmunPharma Loh

Wenn Sie Interesse am Thema "Allergie" haben, sind Sie hier genau richtig.Wir möchten, dass Sie sich bei uns wohlfühlen und möglichst viel Positives mitnehmen

Step Pharma

Step Pharma is focused on the development of a novel class of oral nucleotide synthesis inhibitors targeting CTPS1 for the improved treatment of a range of autoimmune diseases. The company has identified several series of CTPS1 inhibitors, with the most advanced series currently undergoing lead optimization.


Viamet Pharmaceuticals, Inc.

Viamet discovers and develops novel inhibitors of key metalloenzymes via an innovative and proprietary metal-binding approach, the Metallophile™ Technology. Viamet’s disruptive Metallophile™ Technology is based on world-class expertise in bioinorganic chemistry and metalloenzymes and allows Viamet to identify metalloenzyme targets with high therape...

Amura Therapeutics Ltd

Amura has two complementary technology platforms which enable rapid and innovative drug discovery. AMcore™, the bicyclic core molecular scaffold chemistry and the computational screening and design platform, ProtoDiscovery™. Amura has four NCE discovery programmes based on AMcore™: An Osteoporosis programme based on cathepsin K inhibitors A Psoriasis programme based on a cathepsin S inhibit...

KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The initial focus is on inhibitors of plasma kallikrein, which is an important component of the body’s inflammatory response and which, in excess, can l...

Inflection Biosciences Ltd

Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the IBL-300 series (PIM/PI3K/mTOR inhibitors) and IBL-202 (PIM/PI3K inhibito...

Euclises Pharmaceuticals, Inc.

Euclises Pharmaceuticals, Inc. (Euclises) is a drug discovery and development company focused on novel cyclooxygenase-2 (COX-2) inhibitors for use in the oncology setting. Euclises has developed a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary Euclicoxib® platform and is in the process of selecting a lead clinical ...

Innocrin Pharmaceuticals, Inc.

Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer. VT-464 and the entire CYP17 inhibitor patent estate are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as we...

Scantek Medical, Inc

Biopsy and screening clinical trials were conducted at well-established U.S. institutions to assess and validate BreastCare's usefulness in detecting breast cancer. BreastCare was found to be very accurate in terms of the device's documented sensitivity (true positives for cancer) and specificity (true negatives - no cancer detectable by accepted medical methods) indices in relation to the biopsy ...

Probably Relevant

Proteolix, Inc.

Founded in December 2003, Proteolix, Inc. is a privately-held biotechnology company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib, is the first in a new class of selective, irreversible proteasome inhibitors. Prote...

Bioavailability Systems, LLC

BAS was founded in 1996 by James W. Harris, PhD and Robert A. Baugher as a limited liability company incorporated in Maryland. The company's goal was to pursue the identification and commercialization of active anti- First Pass Effect components in grapefruit. In 1997 Dr. Harris successfully isolated compounds from grapefruit demonstrated to be highly active through in-vitro tests as human CYP 3A ...

OncoImmunin Incorporated

OncoImmunin, Inc. was founded by Dr. Akira Komoriya and Dr. Beverly Packard in 1994. The Company has been issued two U.S. patents on its proprietary design for protease inhibitors and fluorogenic substrates. The first PCT application has now entered into national phases in Japan and Europe and a second PCT was filed in 1998.OncoImmunin, Inc. has designed, synthesized, validated, and patented a new...

TopoGEN, Inc

TopoGEN, Inc. provides innovative reagents and kits for topoisomerase research and mechanism-based drug development. Kits are available to assay for topoisomerases (I, II, IV and gyrase) and Tdp1, to assay for topo inhibition in cells and to characterize topoisomerase inhibitors. DNA substrates, topo inhibitors, antibodies, and kit replacement reagents are also available. Products are listed in o...

OncoImmunin, Inc

OncoImmunin, Inc. was founded by Dr. Akira Komoriya and Dr. Beverly Packard in 1994. The Company has been issued three U.S. patents and one Australian patent on its proprietary design for protease inhibitors and fluorogenic substrates. Multiple new applications as well CIP and PCT applications are under review.OncoImmunin, Inc. has designed, synthesized, validated, and patented a new class of prot...

Tensha Therapeutics

Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders. The company’s programs are based on the discovery from the laboratory of Dr. James Bradner at Dana-Farber Cancer Institute of first-in-class, potent small molecule BET bromodomain ...

Cytox Limited

Cytox is a UK company developing products and services for neurodegenerative disorders. The company provides biomarker services to pharmaceutical industry clients conducting clinical trials with drugs for the treatment of Alzheimer's disease (AD) and mild cognitive impairment (MCI). Cytox's blood tests enable the prediction of which patients with MCI will develop AD. The biomarkers are based on th...

Intellikine, Inc.

Intellikine is a private, clinical-stage company focused on the discovery and development of innovative small molecule drugs targeting the PI3K/mTOR pathway. Intellikine recently announced the start of a Phase I trial for INK128, a selective TORC1/2 inhibitor for oncology and is advancing INK1197, a PI3K-delta/gamma dual-selective inhibitor for the treatment of inflammatory and respiratory diseas...

Steroidogenesis Inhibitors International

Drug Discovery

genOway Germany GmbH

The development of a new drug costs roughly 800 M.USD. This huge investment has to cover both the development of the drug itself and the cost of unfruitful work. Dead-ends can represent up to 80% of the total cost of a successful drug. Major challenges in the drug development process are (1) to reduce high failure rates due to faulty candidate selection and false positives and (2) to identify all ...

Peptimmune,Inc

Peptimmune's metabolic disease expertise is based upon polymer chemistry technologyand related ntellectual property assets. Peptimmune is using non-absorbable hydrogelpolymers as fat binding agents to improve the tolerability of lipase inhibitors for thetreatment of obesity. The polymer technology utilizes a proprietary polymer thateliminates fat coalescence. A drug candidate has been identified w...

FLX Bio, Inc.

FLX475 is a best-in-class oral, small molecule antagonist of CCR4. CCR4 ligands are elevated in multiple tumor types when compared to normal tissue. In preclinical studies, FLX475 inhibited tumor growth and increased tumor regression. In addition, FLX475 enhanced the antitumor effects of various checkpoint inhibitors including anti-PD-L1 and anti-CTLA4 ant...

Cyclacel Limited

Cyclacel Limited (Dundee, UK) uses cell cycle control biology and state-of-the-art rational drug design chemistry to develop novel cancer therapeutics including small molecule CDK inhibitors (CYC200; CYC400), Penetratin®-small molecule complexes (CYC300), Pimetic™ small molecules mimicking natural cancer suppressing genes (CYC100), and intelligent delivery and targeting systems (Penetratin® an...

Ayala Pharmaceuticals

Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. The company was founded in November 2017 with an experienced global management team and a strong investor base. The management bench recently expanded with the appointment of Andrea Vergar...

Curaxis Pharmaceutical Corp

Curaxis is an emerging specialty pharmaceutical company with a hormone drug product candidate for the treatment of Alzheimer's disease and multiple cancers. Curaxis' therapeutic platform is based on the hypothesis that many diseases of aging may be caused by age-related changes in the function of the hypothalamic-pituitary-gonadal (HPG) axis. The HPG axis is a hormonal endocrine feedback loop that...


More From BioPortfolio on "More Positives PCSK9 inhibitors Hypothesis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks